Short answer
RECURSION PHARMACEUTICALS, INC. (RXRX) filed an 8-K current report with the SEC on May 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Forward-looking statements concern anticipated performance under the Tempus Agreement and Restated Agreement.
RECURSION PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Forward-looking statements concern anticipated performance under the Tempus Agreement and Restated Agreement
- Outcomes remain subject to execution risks and uncertainties identified in RXRX’s SEC filings
- No historical financial results or quantitative operating metrics provided in this excerpt
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation released May 6, 2026 through the investor-relations website
- Exhibit 99.2 contains the substantive investor materials and may update corporate strategy or operating information
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RECURSION PHARMACEUTICALS, INC. 8-K filings
Get the next RXRX 8-K as it lands
Follow RXRX for push alerts, or ask the research agent what this filing means.